The recent press release is very soft on real detail, however the management of ALT are very careful and cautious on how they roll out this product as it is not a flash in the pants product or something with a limited shelf life due to competition threats -this is a unique product with deep health care professional backing and support.
They are focused on the "long game" with out doubt and not working towards generating short sharp share price movement for traders to capitalise on.
This product will roll out around the world over the next year or two off the back of clinicians recommendations to patients. And it is that type of relationship between the manufacturer and 'coal face' health professional that is the real game changer.
To summaries the short game is to push the price to 10 cents and everyone would be happy... but the long game is to develop a highly profitable company which could succeed in its own right (eg Resmed) or get bought out at $1 by a multinational but that is years away IMO.
There is a lot of water to pass under the bridge with this stock...personally i would forget about it for a while and let it do its thing.
Add to My Watchlist
What is My Watchlist?